Article Text

PDF
The 39 item Parkinson’s disease questionnaire (PDQ-39) revisited: implications for evidence based medicine
  1. Peter Hagell1,2,3,
  2. Carita Nygren1
  1. 1
    Department of Health Sciences, Lund University, Lund, Sweden
  2. 2
    Department of Neurology, University Hospital, Lund, Sweden
  3. 3
    The Vårdal Institute, the Swedish Institute for Health Science, Lund University, Lund, Sweden
  1. Dr Peter Hagell, Department of Health Sciences, Lund University, PO Box 157, SE-221 00 Lund, Sweden; Peter.Hagell{at}med.lu.se

Abstract

Background: The 39 item Parkinson’s disease questionnaire (PDQ-39) is the most widely used patient reported rating scale in Parkinson’s disease. However, several fundamental measurement assumptions necessary for confident use and interpretation of the eight PDQ-39 scales have not been fully addressed.

Methods: Postal survey PDQ-39 data from 202 people with Parkinson’s disease (54% men; mean age 70 years) were analysed regarding psychometric properties using traditional and Rasch measurement methods.

Results: Data quality was good (mean missing item responses, 2%) and there was general support for the legitimacy of summing items within scales without weighting or standardisation. Score reliabilities were adequate (Cronbach’s alpha 0.72–0.95; test–retest 0.76–0.93). The validity of the current grouping of items into scales was not supported by scaling success rates (mean 56.2%), or factor and Rasch analyses. All scales represented more health problems than that experienced by the sample (mean floor effect 15%) and showed compromised score precision towards the less severe end.

Conclusions: Our results provide general support for the acceptability and reliability of the PDQ-39. However, they also demonstrate limitations that have implications for the use of the PDQ-39 in clinical research. The grouping of items into scales appears overly complex and the meaning of scale scores is unclear, which hampers their interpretation. Suboptimal targeting limits measurement precision and, therefore, probably also responsiveness. These observations have implications for the role of the PDQ-39 in clinical trials and evidence based medicine. PDQ-39 derived endpoints should be interpreted and selected cautiously, particularly regarding small but clinically important effects among people with less severe problems.

Statistics from Altmetric.com

Footnotes

  • Funding The study was supported by the Swedish Research Council, the Skane County Council Research and Development Foundation, Rådet för hälso-och sjukvårdsforskning (HSF) and the Department of Nursing. CN was supported by the Section of Occupational Therapy and Gerontology, Lund University, Lund, Sweden.

  • Competing interests: None.

  • Abbreviations:
    ADL
    activities of daily living
    BOD
    bodily discomfort
    COG
    cognitions
    COM
    communication
    DIF
    differential item functioning
    EMO
    emotional well being
    MOB
    mobility
    PD
    Parkinson’s disease
    PDQ-39
    39 item Parkinson’s disease questionnaire
    SOC
    social support
    STI
    stigma

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.